Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Opes Corporation OY operates within the Biotechnology & Pharmaceuticals technology area. The company currently has 1 pending office action, which is being processed through 1 distinct art unit. This focused technological footprint suggests a specific area of innovation for the portfolio. The presence of 1 distinct art unit indicates that the company's current legal challenges are concentrated in a specialized technical field.
The prosecution involves 1 distinct examiner, ensuring a direct point of contact for the pending matter. CHANG, KYUNG SOOK is the busiest examiner assigned to the company. This examiner is responsible for 1 pending office action, which matches the total number of pending office actions for the entire portfolio. This alignment between the workload of CHANG, KYUNG SOOK and the total portfolio workload simplifies the management of the company's current patent applications. Practitioners can focus their strategy on the specific tendencies of this examiner within the Biotechnology & Pharmaceuticals sector.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHANG, KYUNG SOOK | 1 | 60.5% | +40.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18692208 | ACTIVE INGREDIENT DELIVERY SYSTEM | CHANG, KYUNG SOOK | 70d |
| Art Unit | Apps |
|---|---|
| 1613 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18692208 | ACTIVE INGREDIENT DELIVERY SYSTEM | CHANG, KYUNG SOOK | 1613 | §103 | Non-Final OA | 70d | Pending | Mar 14, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialOpes Corporation OY has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Kyung Sook Chang has the most, with 1 of Opes Corporation OY's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
